AP2005003200A0 - Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. - Google Patents

Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.

Info

Publication number
AP2005003200A0
AP2005003200A0 AP2005003200A AP2005003200A AP2005003200A0 AP 2005003200 A0 AP2005003200 A0 AP 2005003200A0 AP 2005003200 A AP2005003200 A AP 2005003200A AP 2005003200 A AP2005003200 A AP 2005003200A AP 2005003200 A0 AP2005003200 A0 AP 2005003200A0
Authority
AP
ARIPO
Prior art keywords
mip
selective inhibitors
receptor ccr1
1alpha
binding
Prior art date
Application number
AP2005003200A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Cheryl M Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2005003200A0 publication Critical patent/AP2005003200A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2005003200A 2002-07-18 2003-07-07 Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. AP2005003200A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
PCT/IB2003/002876 WO2004009550A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1

Publications (1)

Publication Number Publication Date
AP2005003200A0 true AP2005003200A0 (en) 2005-03-31

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003200A AP2005003200A0 (en) 2002-07-18 2003-07-07 Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.

Country Status (24)

Country Link
US (1) US20040063759A1 (es)
EP (1) EP1534677A1 (es)
JP (1) JP2005537279A (es)
KR (1) KR20050021497A (es)
CN (1) CN1668592A (es)
AP (1) AP2005003200A0 (es)
AR (1) AR040583A1 (es)
AU (1) AU2003242941A1 (es)
BR (1) BR0312946A (es)
CA (1) CA2492651A1 (es)
EC (1) ECSP055547A (es)
HN (1) HN2003000222A (es)
IL (1) IL166010A0 (es)
IS (1) IS7614A (es)
MA (1) MA27326A1 (es)
MX (1) MXPA05000380A (es)
OA (1) OA12885A (es)
PA (1) PA8575901A1 (es)
PE (1) PE20040666A1 (es)
TN (1) TNSN05014A1 (es)
TW (1) TW200402416A (es)
UY (1) UY27897A1 (es)
WO (1) WO2004009550A1 (es)
ZA (1) ZA200500067B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
CN1867336B (zh) 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
MXPA05000757A (es) * 2002-07-18 2005-04-19 Pfizer Prod Inc Derivados de piperidina biciclicos como antagonistas del receptor de quimioquina ccr1.
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
KR101281435B1 (ko) 2005-07-26 2013-07-02 글락소 그룹 리미티드 벤질피페라진 유도체 및 그의 의학적 용도
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
WO2009051244A1 (ja) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
WO2010077915A1 (en) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
CA2373942A1 (en) * 1999-05-18 2000-11-23 Teijin Limited Remedies or prophylactis for diseases in association with chemokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
IL159393A (en) * 2001-07-24 2011-01-31 Richter Gedeon Vegyeszet Piperidine derivatives, pharmaceutical compositions containing them, processes for their preparation and uses thereof

Also Published As

Publication number Publication date
MXPA05000380A (es) 2005-03-31
PE20040666A1 (es) 2004-09-25
JP2005537279A (ja) 2005-12-08
WO2004009550A1 (en) 2004-01-29
UY27897A1 (es) 2004-02-27
KR20050021497A (ko) 2005-03-07
MA27326A1 (fr) 2005-05-02
AR040583A1 (es) 2005-04-13
PA8575901A1 (es) 2004-07-20
IL166010A0 (en) 2006-01-15
IS7614A (is) 2004-12-23
AU2003242941A1 (en) 2004-02-09
US20040063759A1 (en) 2004-04-01
CN1668592A (zh) 2005-09-14
TNSN05014A1 (fr) 2007-05-14
HN2003000222A (es) 2004-11-23
ECSP055547A (es) 2005-03-10
EP1534677A1 (en) 2005-06-01
OA12885A (en) 2006-09-15
TW200402416A (en) 2004-02-16
CA2492651A1 (en) 2004-01-29
ZA200500067B (en) 2005-11-02
BR0312946A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
AP2005003200A0 (en) Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
IL173398A0 (en) Pyridyl derivatives and their use as therapeutic agents
HK1094203A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AP2006003770A0 (en) Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
EP1843768A4 (en) SUBSTITUTED MORPHINANES AND METHODS OF USE
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
ZA200606070B (en) Substituted quinolines and their use as mycrobacterial inhibitors
IL174497A0 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003215756A8 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
EP1703907A4 (en) COMPOSITIONS AND METHODS FOR TREATING RECURRENT CONDITIONS
AU2003269421A8 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
EP1627048A4 (en) Compositions for Downregulating CCR5 Expression and Method of Use Therefor
EP1670314A4 (en) METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
EP1542972A4 (en) CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITION AND METHOD OF USE
EP1601348A4 (en) Compositions and methods with improved therapeutic activity
IL177197A0 (en) Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
GB0611789D0 (en) Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
AU2003263988A8 (en) Methods and compositions to treat conditions associated with neovascularization